-
公开(公告)号：EP4282986A3
公开(公告)日：2024-02-28
申请号：EP23199877.4
申请日：2018-03-23
IPC分类号： C12Q1/6888 , C12Q1/70
摘要： There is disclosed a composition or kit comprising at least a first HPIV-2 amplification oligomer and a second HPIV-2 amplification oligomer, wherein: the first HPIV-2 amplification oligomer and second HPIV-2 amplification oligomer are configured to amplify an HPIV-2 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-2 position located within HPIV-2 positions 1600-1700.
-
公开(公告)号：EP4279613A2
公开(公告)日：2023-11-22
申请号：EP23200155.2
申请日：2018-03-23
IPC分类号： C12Q1/70
摘要： There is disclosed a composition or kit for detecting two or more of HPIV-1, HPIV-2, HPIV-3 or HPIV-4 comprising two or more first and second amplification oligomers selected from: (A) first and second HPIV-1 amplification oligomers; (B) first and second HPIV-2 amplification oligomers; (C) first and second HPIV-3 amplification oligomers; and (D) first and second HPIV-4 amplification oligomers, wherein (A) the first HPIV-1 amplification oligomer and the second HPIV-1 amplification oligomer is configured to amplify an HPIV-1 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-1 position located within HPIV-1 positions 330-490 or 960-1100; (B) the first HPIV-2 amplification oligomer and the second HPIV-2 amplification oligomer are configured to amplify an HPIV-2 amplicon of at least about 50 nucleotides in length and comprising at least one HPIV-2 position located within HPIV-2 positions 1600-1700; (C) the first HPIV-3 amplification oligomer and the second HPIV-3 amplification oligomer are configured to amplify an HPIV-3 amplicon of at least about 50 nucleotides in length comprising at least one Human Parainfluenza Virus 3 (HPIV-3) position located in the range of positions 1295-1305, 1350-1360, and/or 1380-1390; or the first HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1270 and the second HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1355, and the first and second HPIV-3 amplification oligomers are configured to produce an HPIV-3 amplicon; or the first HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1355 and the second HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1437, and the first and second amplification oligomers are configured to produce an HPIV-3 amplicon; or (D) the first HPIV-4 amplification oligomer and second HPIV-4 amplification oligomer are configured to amplify an HPIV-4 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-4 position located within HPIV-4 positions 620-740, 2130-2410, 2520-3040, or 10090-11980.
-
公开(公告)号：EP4219770A3
公开(公告)日：2023-08-16
申请号：EP23159203.1
申请日：2018-03-23
摘要： A kit for analysis of a Respiratory Syncytial Virus B (RSV B) target nucleic acid molecule species that may be present in a biological sample, comprising: an RSV B primer pair for generating an RSV B amplicon if RSV B is present in the biological sample, the RSV B primer pair comprising a first RSV B primer and a second RSV B primer, wherein: (i) the first RSV B primer is substantially complementary to a first RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:99 to 101 and 106; and (ii) the second RSV B primer is substantially complementary to a second RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS: 104 to 106 &115.
-
公开(公告)号：EP3601617A1
公开(公告)日：2020-02-05
申请号：EP18716844.8
申请日：2018-03-23
IPC分类号： C12Q1/6888 , C12Q1/70
-
5.发明公开
公开(公告)号：EP4382619A2
公开(公告)日：2024-06-12
申请号：EP24168848.0
申请日：2018-03-23
IPC分类号： C12Q1/6888
CPC分类号： C12Q1/701 , C12Q2600/1620130101 , C12Q1/6888
摘要： There is disclosed a composition comprising a combination of amplification oligomers configured for amplification of an Adenovirus target nucleic acid and at least one additional target nucleic acid selected from the group consisting of a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, wherein: (A) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer and a second Adenovirus amplification oligomer are configured to amplify an Adenovirus amplicon of at least about 50 nucleotides in length comprising at least one Adenovirus position located in the range of nucleotide positions 52 to 74 of SEQ ID NO:47, nucleotide positions 76 to 99 of SEQ ID NO:47, nucleotide positions 40 to 56 of SEQ ID NO:47, nucleotide positions 65 to 87 of SEQ ID NO:47, nucleotide positions 1 to 18 of SEQ ID NO:47, nucleotide positions 7 to 23 of SEQ ID NO:47, nucleotide positions 28 to 45 of SEQ ID NO:47, nucleotide positions 27 to 45 of SEQ ID NO:47, nucleotide positions 26 to 45 of SEQ ID NO:47, nucleotide positions 139 to 155 of SEQ ID NO:47, nucleotide positions 103 to 123 of SEQ ID NO:47, nucleotide positions 159 to 175 of SEQ ID NO:47, nucleotide positions 83 to 99 of SEQ ID NO:47, and/or nucleotide positions 83 to 98 of SEQ ID NO:47; and (B) for the at least one additional target nucleic acid, (1) a first Metapneumovirus amplification oligomer and a second Metapneumovirus amplification oligomer are configured to amplify a Metapneumovirus amplicon of at least about 50 nucleotides in length comprising at least one Metapneumovirus position located in the range of nucleotide positions 966 to 1147 of SEQ ID NO:150, nucleotides 844 to 1027 of SEQ ID NO:159, nucleotide positions 1000 to 1040 of SEQ ID NO:150, nucleotide positions 880 to 915 of SEQ ID NO:159, nucleotide positions 1027 to 1080 of SEQ ID NO:150, nucleotide positions 913 to 958 of SEQ ID NO:159, nucleotide positions 1073 to 1115 of SEQ ID NO:150, and/or nucleotide positions 953 to 995 of SEQ ID NO:159; and/or (2) a first Rhinovirus amplification oligomer and a second Rhinovirus amplification oligomer are configured to amplify a Rhinovirus amplicon of at least 50 nucleotides in length comprising at least one Rhinovirus position located in the range of nucleotide positions 230 to 556 of SEQ ID NO:120, nucleotide positions 199 to 525 of SEQ ID NO:101, nucleotide positions 80 to 410 of SEQ ID NO:76, nucleotide positions 263 to 303 of SEQ ID NO:120, nucleotide positions 231 to 264 of SEQ ID NO:101, nucleotide positions 106 to 156 of SEQ ID NO:76, nucleotide positions 312 to 346 of SEQ ID NO:120, nucleotide positions 279 to 314 of SEQ ID NO:101, nucleotide positions 455 to 506 of SEQ ID NO:76, nucleotide positions 480 to 533 of SEQ ID NO:120, nucleotide positions 455 to 506 of SEQ ID NO:101, and/or nucleotide positions 338 to 397 of SEQ ID NO:76.
-
公开(公告)号：EP4219771A3
公开(公告)日：2023-08-16
申请号：EP23159381.5
申请日：2018-03-23
摘要： A kit for analysis of two or more of Flu A, Flu B, RSV A, and/or RSV B that may be present in a biological sample, comprising two or more of the primer pairs set forth in (a), (b), (c), (d) and (e): (a) a first Influenza A (Flu A) primer pair for generating a first Flu A amplicon if Flu A is present in the biological sample, the first Flu A primer pair comprising a first Flu A primer and a second Flu A primer, wherein: (i) the first Flu A primer that is substantially complementary to a first Flu A target nucleic acid sequence, is about 18 to about 100 contiguous bases in length and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NO: I and SEQ ID NO:23; and (ii) the second Flu A primer that is substantially complementary to a second Flu A target nucleic acid, is about 18 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NO:25 and SEQ ID NO:28; and (b) a second Flu A primer pair for generating a second Flu A amplicon if Flu A is present in the biological sample, the second Flu A primer pair comprising a third Flu A primer and a fourth Flu A primer, wherein: (1) the third Flu A primer that is substantially complementary to a third Flu A target nucleic acid sequence , is about 19 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS;2 to 5 and 24; and (ii) the fourth Flu A primer that is substantially complementary to a fourth Flu A target nucleic acid sequence, is about 20 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:26 & 27; and (c) an Influenza B (Flu B) primer pair for generating a Flu B amplicon if Flu B is present in the biological sample, the Flu B primer pair comprising a first Flu B primer and a second Flu B primer, wherein: (i) the first Flu B primer that is substantially complementary to a first Flu B target nucleic acid sequence, is about 22 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting SEQ ID NOS;29 & 67; and (ii) the second Flu B primer that is substantially complementary to a second Flu B target nucleic acid sequence, is about 21 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:68 to 70; and (d) a Respiratory Syncytial Virus A (RSV A) primer pair for generating an RSV A amplicon if RSV A is present in the biological sample, the RSV A primer pair comprising a first RSV A primer and a second RSV A primer, wherein: (i) the first RSV A primer that is substantially complementary to a first RSV A target nucleic acid sequence, is about 26 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:79 & 88; and (ii) the second RSV A primer that is substantially complementary to a second RSV A target nucleic acid sequence, is about 22 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:72 to 74 & 92 to 96; and (e) a Respiratory Syncytial Virus B (RSV B) primer pair for generating an RSV B amplicon if RSV B is present in the biological sample, the RSV B primer pair comprising a first RSV B primer and a second RSV B primer, wherein: (i) the first RSV B primer is substantially complementary to a first RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:99 to 101 and 106; and (ii) the second RSV B primer is substantially complementary to a second RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS: 104 to 106 & 115.
-
公开(公告)号：EP4212634A1
公开(公告)日：2023-07-19
申请号：EP23158592.8
申请日：2018-03-23
IPC分类号： C12Q1/70
摘要： A kit for analysis of an Influenza B (Flu B) target nucleic acid molecule species that may be present in a biological sample, comprising: a Flu B primer pair for generating a Flu B amplicon if Flu B is present in the biological sample, the Flu B primer pair comprising a first Flu B primer and a second Flu B primer, wherein: (i) the first Flu B primer that is substantially complementary to a first Flu B target nucleic acid sequence, is about 22 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting SEQ ID NOS: 29 & 67; and (ii) the second Flu B primer that is substantially complementary to a second Flu B target nucleic acid sequence, is about 21 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS: 68 to 70.
-
公开(公告)号：EP4282986A2
公开(公告)日：2023-11-29
申请号：EP23199877.4
申请日：2018-03-23
IPC分类号： C12Q1/70
摘要： There is disclosed a composition or kit comprising at least a first HPIV-2 amplification oligomer and a second HPIV-2 amplification oligomer, wherein: the first HPIV-2 amplification oligomer and second HPIV-2 amplification oligomer are configured to amplify an HPIV-2 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-2 position located within HPIV-2 positions 1600-1700.
-
公开(公告)号：EP4219770A2
公开(公告)日：2023-08-02
申请号：EP23159203.1
申请日：2018-03-23
IPC分类号： C12Q1/70
摘要： A kit for analysis of a Respiratory Syncytial Virus B (RSV B) target nucleic acid molecule species that may be present in a biological sample, comprising: an RSV B primer pair for generating an RSV B amplicon if RSV B is present in the biological sample, the RSV B primer pair comprising a first RSV B primer and a second RSV B primer, wherein: (i) the first RSV B primer is substantially complementary to a first RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:99 to 101 and 106; and (ii) the second RSV B primer is substantially complementary to a second RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS: 104 to 106 &115.
-
公开(公告)号：EP1786916B1
公开(公告)日：2013-05-08
申请号：EP05791220.6
申请日：2005-08-26
发明人： BECKER, Michael M. , LAM, Wai-Chung , LIVEZEY, Kristin W. , BRENTANO, Steven T. , KOLK, Daniel P. , SCHRODER, Astrid R. W.
CPC分类号： C12P19/34 , C12Q1/6865 , C12Q2537/163 , C12Q2521/325 , C12Q2521/107 , C12Q2525/186 , C12Q2533/101 , C12Q2525/143
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.016 秒)
